Table 3.
Proportion Enrolled on Trial by Diagnosis
| Total | < 2007 | ≥ 2007 | P Value* | |
|---|---|---|---|---|
| N = 4608 | N = 4596 | |||
| Leukemia | 1199/2699 (44.4%) | 547/1362 (40.2%) | 652/1337 (48.8%) | |
| Acute lymphoblastic leukemia | 1043/2138 (48.8%) | 484/1075 (45.0%) | 559/1063 (52.6%) | 0.0006 |
| Acute myeloid leukemia | 138/395 (34.9%) | 50/192 (26.0%) | 88/203 (43.3%) | 0.0005 |
| Other leukemias | 18/166 (10.8%) | 13/95 (13.7%) | 5/71 (7.0%) | 0.267 |
| Lymphoma | 270/962 (28.1%) | 167/504 (33.1%) | 103/458 (22.5%) | |
| Hodgkin lymphoma | 130/400 (32.5%) | 61/200 (30.5%) | 69/200 (34.5%) | 0.455 |
| Non-Hodgkin lymphoma excluding Burkitt’s lymphoma | 90/340 (26.5%) | 64/180 (35.6%) | 26/160 (16.3%) | <0.0001 |
| Burkitt’s lymphoma | 37/162 (22.8%) | 31/91 (34.1%) | 6/71 (8.5%) | 0.0002 |
| Other lymphomas | 13/60 (21.7%) | 11/33 (33.3%) | 2/27 (7.4%) | 0.035 |
| Solid Tumors | 827/3187 (25.9%) | 435/1556 (28.0%) | 392/1631 (24.0%) | |
| Ewing sarcoma | 63/164 (38.4%) | 39/82 (47.6%) | 24/82 (29.3%) | 0.025 |
| Hepatoblastoma | 22/139 (15.8%) | 15/70 (21.4%) | 7/69 (10.1%) | 0.112 |
| Neuroblastoma and ganglioneuroblastoma | 237/734 (32.3%) | 140/363 (38.6%) | 97/371 (26.1%) | 0.0004 |
| Osteosarcoma | 78/207 (37.7%) | 35/98 (35.7%) | 43/109 (39.4%) | 0.682 |
| Rhabdomyosarcoma | 121/273 (44.3%) | 68/135 (50.4%) | 53/138 (38.4%) | 0.062 |
| Wilms tumor | 160/424 (37.7%) | 66/204 (32.4%) | 94/220 (42.7%) | 0.036 |
| Other solid tumors | 146/1246 (11.7%) | 72/604 (11.9%) | 74/642 (11.5%) | 0.898 |
| Central Nervous System Tumors | 237/2307 (10.3%) | 134/1167 (11.5%) | 103/1140 (9.0%) | |
| Astrocytoma | 52/982 (5.3%) | 26/508 (5.1%) | 26/474 (5.5%) | 0.909 |
| Ependymoma | 38/197 (19.3%) | 24/93 (25.8%) | 14/104 (13.5%) | 0.044 |
| Medulloblastoma | 36/172 (20.9%) | 15/88 (17.0%) | 21/84 (25.0%) | 0.274 |
| Other central nervous system tumors | 111/956 (11.6%) | 69/478 (14.4%) | 42/478 (8.8%) | 0.009 |
*P values by Chi square test